BR112018014222A2 - método de tratamento da glomerulopatia c3 - Google Patents
método de tratamento da glomerulopatia c3Info
- Publication number
- BR112018014222A2 BR112018014222A2 BR112018014222-0A BR112018014222A BR112018014222A2 BR 112018014222 A2 BR112018014222 A2 BR 112018014222A2 BR 112018014222 A BR112018014222 A BR 112018014222A BR 112018014222 A2 BR112018014222 A2 BR 112018014222A2
- Authority
- BR
- Brazil
- Prior art keywords
- glomerulopathy
- treatment method
- human
- susceptible
- administering
- Prior art date
Links
- 208000029574 C3 glomerulopathy Diseases 0.000 title abstract 2
- 208000027134 non-immunoglobulin-mediated membranoproliferative glomerulonephritis Diseases 0.000 title abstract 2
- 229940126681 complement 5a receptor antagonist Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| BR122024002810-7A BR122024002810A2 (pt) | 2016-01-14 | 2017-01-12 | Usos de composto antagonista de c5ar |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662278788P | 2016-01-14 | 2016-01-14 | |
| US62/278,788 | 2016-01-14 | ||
| US201662280346P | 2016-01-19 | 2016-01-19 | |
| US62/280,346 | 2016-01-19 | ||
| US201662347450P | 2016-06-08 | 2016-06-08 | |
| US62/347,450 | 2016-06-08 | ||
| US201662397527P | 2016-09-21 | 2016-09-21 | |
| US62/397,527 | 2016-09-21 | ||
| PCT/US2017/013132 WO2017123716A1 (en) | 2016-01-14 | 2017-01-12 | Method of treating c3 glomerulopathy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112018014222A2 true BR112018014222A2 (pt) | 2018-12-11 |
Family
ID=59312069
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112018014222-0A BR112018014222A2 (pt) | 2016-01-14 | 2017-01-12 | método de tratamento da glomerulopatia c3 |
| BR122024002810-7A BR122024002810A2 (pt) | 2016-01-14 | 2017-01-12 | Usos de composto antagonista de c5ar |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR122024002810-7A BR122024002810A2 (pt) | 2016-01-14 | 2017-01-12 | Usos de composto antagonista de c5ar |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US20170202821A1 (enExample) |
| EP (1) | EP3402486B1 (enExample) |
| JP (3) | JP7339733B2 (enExample) |
| KR (1) | KR102767008B1 (enExample) |
| CN (1) | CN108601790A (enExample) |
| AU (1) | AU2017207359C1 (enExample) |
| BR (2) | BR112018014222A2 (enExample) |
| CA (1) | CA3010735C (enExample) |
| ES (1) | ES3026359T3 (enExample) |
| IL (1) | IL260539B (enExample) |
| MA (1) | MA43872A (enExample) |
| MX (2) | MX2018008624A (enExample) |
| NZ (1) | NZ744083A (enExample) |
| RU (1) | RU2742888C2 (enExample) |
| SG (1) | SG11201805828YA (enExample) |
| TW (1) | TWI791423B (enExample) |
| WO (1) | WO2017123716A1 (enExample) |
| ZA (1) | ZA201804513B (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2577548T3 (es) | 2008-12-22 | 2016-07-15 | Chemocentryx, Inc. | Antagonistas de C5aR |
| US9126939B2 (en) | 2010-06-24 | 2015-09-08 | Pingchen Fan | C5AR antagonists |
| CN106999481B (zh) | 2014-09-29 | 2021-04-16 | 凯莫森特里克斯股份有限公司 | 制备C5aR拮抗剂的方法和中间体 |
| WO2017035405A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Amino compounds for treatment of immune and inflammatory disorders |
| EP3340983B1 (en) | 2015-08-26 | 2023-10-04 | Achillion Pharmaceuticals, Inc. | Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders |
| AR106018A1 (es) | 2015-08-26 | 2017-12-06 | Achillion Pharmaceuticals Inc | Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos |
| WO2017035401A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Amide compounds for treatment of immune and inflammatory disorders |
| MA43872A (fr) | 2016-01-14 | 2021-05-19 | Chemocentryx Inc | Procédé de traitement d'une glomérulopathie à c3 |
| WO2018160891A1 (en) | 2017-03-01 | 2018-09-07 | Achillion Pharmaceutical, Inc. | Pharmaceutical compounds for treatment of medical disorders |
| CN110603252A (zh) | 2017-03-01 | 2019-12-20 | 艾其林医药公司 | 用于治疗医学障碍的芳基、杂芳基和杂环药物化合物 |
| WO2019021091A1 (en) * | 2017-07-27 | 2019-01-31 | Procter & Gamble International Operations Sa | SPRAYABLE, STABLE PHASE REFRIGERATING COMPOSITIONS COMPRISING SUSPENDED PARTICLES |
| EP3661493A4 (en) | 2017-08-02 | 2021-04-14 | Achillion Pharmaceuticals, Inc. | TREATMENT DIET FOR THE TREATMENT OF PAROXYSTIC NOCTURAL HEMOGLOBINURIA |
| WO2019227102A1 (en) * | 2018-05-25 | 2019-11-28 | Achillion Pharmaceuticals, Inc. | Complement alternative pathway-associated nephropathy biomarkers |
| MX2021002640A (es) * | 2018-09-06 | 2021-07-16 | Achillion Pharmaceuticals Inc | Formas morficas de los inhibidores del factor d del complemento. |
| US11814391B2 (en) | 2018-09-06 | 2023-11-14 | Achillion Pharmaceuticals, Inc. | Macrocyclic compounds for the treatment of medical disorders |
| EP3856164B1 (en) | 2018-09-25 | 2024-08-07 | Achillion Pharmaceuticals, Inc. | Morphic forms of complement factor d inhibitors |
| PL3886820T3 (pl) | 2018-11-30 | 2023-08-14 | Chemocentryx, Inc. | Postacie użytkowe będące kapsułkami |
| US12239645B2 (en) | 2018-12-17 | 2025-03-04 | Achillion Pharmaceuticals, Inc. | Targeted dosing for the treatment of complement mediated disorders |
| WO2020182384A1 (en) | 2019-03-11 | 2020-09-17 | Inflarx Gmbh | Fused piperidinyl bicyclic and related compounds as modulators of c5a receptor |
| JP7635138B2 (ja) | 2019-03-22 | 2025-02-25 | アキリオン ファーマシューティカルズ， インコーポレーテッド | 補体媒介性障害の治療のための医薬化合物 |
| AU2021321901A1 (en) * | 2020-08-07 | 2023-03-09 | Kira Pharmaceuticals (Suzhou) Ltd. | Compounds as C5ar inhibitors |
| US20220257580A1 (en) * | 2020-12-21 | 2022-08-18 | Chemocentryx, Inc. | Treatment of c3 glomerulopathy using a c5a inhibitor |
| CN115192563B (zh) * | 2022-05-09 | 2023-10-13 | 北京大学第一医院 | C3a/C3aR通路拮抗剂治疗原发性膜性肾病的用途 |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1268002A (en) | 1917-09-12 | 1918-05-28 | William M Goodwin | Measuring instrument. |
| US4166452A (en) | 1976-05-03 | 1979-09-04 | Generales Constantine D J Jr | Apparatus for testing human responses to stimuli |
| US4256108A (en) | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
| US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
| US4686100A (en) | 1985-04-02 | 1987-08-11 | The Board Of Trustees Of The Leland Stanford Junior University | Method for the treatment of adult respiratory distress syndrome |
| BR9913654A (pt) | 1998-08-28 | 2001-11-27 | Scios Inc | Inibidores de p-38alfa quinase |
| RU2197288C2 (ru) * | 1999-08-03 | 2003-01-27 | Тверская медицинская академия | Способ лечения больных хроническим гломерулонефритом |
| WO2001085720A1 (en) | 2000-05-05 | 2001-11-15 | Smithkline Beecham Corporation | Novel anti-infectives |
| ES2353077T3 (es) | 2000-08-10 | 2011-02-25 | Mitsubishi Tanabe Pharma Corporation | Derivados de urea con sustitución en posición 3 y uso medicinal de los mismos. |
| CN102050758A (zh) | 2000-09-14 | 2011-05-11 | 田边三菱制药株式会社 | 酰胺衍生物及其制备药物的用途 |
| YU23503A (sh) | 2000-09-29 | 2006-03-03 | Neurogen Corporation | Mali molekuli kao modulatori receptora c5a visokog afiniteta |
| US7432356B2 (en) | 2001-08-17 | 2008-10-07 | Genentech, Inc. | Complement pathway inhibitors binding to C5 and C5a without preventing formation of C5b |
| CN100488958C (zh) | 2001-09-21 | 2009-05-20 | 三菱制药株式会社 | 3-取代的-4-嘧啶酮衍生物 |
| ITMI20012025A1 (it) | 2001-09-28 | 2003-03-28 | Dompe Spa | Sali di ammonio quaternari di omega-amminoalchilammidi di acidi r 2-aril-propionici e composizioni farmaceutiche che li contengono |
| US20030195192A1 (en) | 2002-04-05 | 2003-10-16 | Fortuna Haviv | Nicotinamides having antiangiogenic activity |
| AU2003218374A1 (en) | 2002-03-28 | 2003-10-13 | Neurogen Corporation | Substituted tetrahydroisoquinolines as c5a receptor modulators |
| WO2003082826A1 (en) | 2002-03-28 | 2003-10-09 | Neurogen Corporation | Substituted biaryl amides as c5a receptor modulators |
| US20040014782A1 (en) | 2002-03-29 | 2004-01-22 | Krause James E. | Combination therapy for the treatment of diseases involving inflammatory components |
| US20040014744A1 (en) | 2002-04-05 | 2004-01-22 | Fortuna Haviv | Substituted pyridines having antiangiogenic activity |
| US7138420B2 (en) | 2002-08-08 | 2006-11-21 | Boehringer Ingelheim Pharmaceuticals Inc. | Substituted benzimidazole compounds |
| US7169775B2 (en) | 2002-08-21 | 2007-01-30 | Neurogen Corporation | Amino methyl imidazoles as C5a receptor modulators |
| US7455837B2 (en) | 2002-11-05 | 2008-11-25 | The Regents Of The University Of Michigan | Compositions and methods for the diagnosis and treatment of sepsis |
| FR2846654A1 (fr) | 2002-11-05 | 2004-05-07 | Servier Lab | Nouveaux derives de la 2,3-dihydro-4(1h)-pyridinone, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| US7342115B2 (en) | 2002-11-08 | 2008-03-11 | Neurogen Corporation | 3-substituted-6-aryl pyridines |
| AU2003902354A0 (en) | 2003-05-15 | 2003-05-29 | Harkin, Denis W. | Treatment of haemorrhagic shock |
| JP2006527756A (ja) | 2003-06-19 | 2006-12-07 | ファイザー・プロダクツ・インク | Ｎｋ１拮抗薬 |
| US20060154917A1 (en) | 2003-07-03 | 2006-07-13 | Neurogen Corporation | Substituted (heterocycloalkyl)methyl azole derivatives as c5a receptor modulators |
| GB0325956D0 (en) | 2003-11-06 | 2003-12-10 | Addex Pharmaceuticals Sa | Novel compounds |
| BRPI0512535A (pt) | 2004-06-24 | 2008-03-25 | Incyte Corp | compostos de piperidinas n-substituìdas, suas composições e métodos de modulações |
| WO2006071958A1 (en) | 2004-12-29 | 2006-07-06 | Millennium Pharmaceuticals, Inc. | Compounds useful as chemokine receptor antagonists |
| WO2006087543A1 (en) | 2005-02-18 | 2006-08-24 | Astrazeneca Ab | Antibacterial piperidine derivatives |
| WO2007035428A1 (en) | 2005-09-15 | 2007-03-29 | Bristol-Myers Squibb Company | Met kinase inhibitors |
| US20070112015A1 (en) | 2005-10-28 | 2007-05-17 | Chemocentryx, Inc. | Substituted dihydropyridines and methods of use |
| RU2458051C2 (ru) | 2005-11-24 | 2012-08-10 | ДОМПЕ ФА.Р.МА С.п.А. | (r)-арилалкиламинопроизводные и содержащие их фармацевтические композиции |
| DK2359834T5 (en) * | 2006-03-15 | 2017-02-06 | Alexion Pharma Inc | Treatment of paroxysmal nocturnal hemoglobinuria patients with a complement inhibitor |
| WO2008022060A2 (en) | 2006-08-14 | 2008-02-21 | Novartis Ag | Imidazo-pyridine derivatives for modulating protein kinase activity |
| US8198266B2 (en) * | 2006-10-31 | 2012-06-12 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Use of an EGFR antagonist for the treatment of glomerolonephritis |
| RU2010102899A (ru) | 2007-06-29 | 2011-08-10 | Торрент Фармасьютикалз Лтд. (In) | Новые замещенные пиперидоны в качестве индукторов hsp |
| WO2010019210A2 (en) | 2008-08-11 | 2010-02-18 | President And Fellows Of Harvard College | Halofuginone analogs for inhibition of trna synthetases and uses thereof |
| US20110172126A1 (en) | 2008-09-03 | 2011-07-14 | Xenome Ltd | Libraries of peptide conjugates and methods for making them |
| US20100074863A1 (en) | 2008-09-17 | 2010-03-25 | Yat Sun Or | Anti-infective pyrrolidine derivatives and analogs |
| RS64039B1 (sr) | 2008-11-10 | 2023-04-28 | Alexion Pharma Inc | Metode i kompozicije za lečenje poremećaja povezanih sa komplementom |
| ES2577548T3 (es) | 2008-12-22 | 2016-07-15 | Chemocentryx, Inc. | Antagonistas de C5aR |
| US20110275639A1 (en) | 2008-12-22 | 2011-11-10 | Chemocentryx, Inc. | C5aR ANTAGONISTS |
| WO2011035143A2 (en) | 2009-09-17 | 2011-03-24 | The Regents Of The University Of Michigan | Methods and compositions for inhibiting rho-mediated diseases and conditions |
| US9126939B2 (en) * | 2010-06-24 | 2015-09-08 | Pingchen Fan | C5AR antagonists |
| US8147400B1 (en) * | 2011-01-17 | 2012-04-03 | Coloplast A/S | Penile implant with dilatant liquid |
| EP2864322B1 (en) * | 2012-06-20 | 2016-04-27 | Novartis AG | Complement pathway modulators and uses thereof |
| DK2994488T3 (da) | 2013-05-08 | 2022-10-03 | Novo Nordisk As | Anvendelse af c5ar-antagonister |
| CN106999481B (zh) | 2014-09-29 | 2021-04-16 | 凯莫森特里克斯股份有限公司 | 制备C5aR拮抗剂的方法和中间体 |
| MA43872A (fr) | 2016-01-14 | 2021-05-19 | Chemocentryx Inc | Procédé de traitement d'une glomérulopathie à c3 |
| NZ747259A (en) | 2016-04-04 | 2022-11-25 | Chemocentryx Inc | Soluble c5ar antagonists |
| US20220257580A1 (en) | 2020-12-21 | 2022-08-18 | Chemocentryx, Inc. | Treatment of c3 glomerulopathy using a c5a inhibitor |
-
2017
- 2017-01-12 MA MA043872A patent/MA43872A/fr unknown
- 2017-01-12 AU AU2017207359A patent/AU2017207359C1/en active Active
- 2017-01-12 MX MX2018008624A patent/MX2018008624A/es unknown
- 2017-01-12 BR BR112018014222-0A patent/BR112018014222A2/pt not_active Application Discontinuation
- 2017-01-12 EP EP17738902.0A patent/EP3402486B1/en active Active
- 2017-01-12 BR BR122024002810-7A patent/BR122024002810A2/pt not_active Application Discontinuation
- 2017-01-12 KR KR1020187023360A patent/KR102767008B1/ko active Active
- 2017-01-12 TW TW106100938A patent/TWI791423B/zh active
- 2017-01-12 CN CN201780006962.XA patent/CN108601790A/zh active Pending
- 2017-01-12 WO PCT/US2017/013132 patent/WO2017123716A1/en not_active Ceased
- 2017-01-12 RU RU2018129378A patent/RU2742888C2/ru active
- 2017-01-12 NZ NZ744083A patent/NZ744083A/en unknown
- 2017-01-12 JP JP2018536408A patent/JP7339733B2/ja active Active
- 2017-01-12 MX MX2022006069A patent/MX2022006069A/es unknown
- 2017-01-12 CA CA3010735A patent/CA3010735C/en active Active
- 2017-01-12 ES ES17738902T patent/ES3026359T3/es active Active
- 2017-01-12 US US15/404,610 patent/US20170202821A1/en not_active Abandoned
- 2017-01-12 SG SG11201805828YA patent/SG11201805828YA/en unknown
-
2018
- 2018-07-06 ZA ZA2018/04513A patent/ZA201804513B/en unknown
- 2018-07-11 IL IL260539A patent/IL260539B/en active IP Right Grant
- 2018-11-08 US US16/184,535 patent/US11285138B2/en active Active
-
2022
- 2022-02-14 US US17/670,604 patent/US11779576B2/en active Active
-
2023
- 2023-06-20 JP JP2023100664A patent/JP2023126235A/ja active Pending
-
2024
- 2024-06-06 JP JP2024092498A patent/JP2024110998A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112018014222A2 (pt) | método de tratamento da glomerulopatia c3 | |
| CY1122603T1 (el) | Γαμμα-δικετονες για τη θεραπευτικη αντιμετωπιση και την προληψη της γηρανσης του δερματος και των ρυτιδων | |
| MX2020001774A (es) | Composiciones y métodos para tratar enfermedad colestásica. | |
| PH12019500204A1 (en) | Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders | |
| MA46098A (fr) | Méthodes de prévention ou de traitement de l'allergie par administration d'un antagoniste d'il-4 r | |
| BR112017015059A2 (pt) | inibidor de proteassoma e uso | |
| EP3368560A4 (en) | CPG REDUCED FACTOR VIII VARIATIONS, COMPOSITIONS AND METHODS AND USES FOR THE TREATMENT OF HEMOSTASIS | |
| BR112014021104A2 (pt) | métodos e composições para o tratamento da doença de huntington | |
| BR112017008093A2 (pt) | processos para tratamento de doenças oculares | |
| EA201890394A1 (ru) | КОМПОЗИЦИИ НА ОСНОВЕ iRNA ДЛЯ ТРАНСТИРЕТИНА (TTR) И СПОСОБЫ ИХ ПРИМЕНЕНИЯ ДЛЯ ЛЕЧЕНИЯ ИЛИ ПРЕДУПРЕЖДЕНИЯ АССОЦИИРОВАННЫХ С TTR ЗАБОЛЕВАНИЙ | |
| MA40240A (fr) | Composés hétéroaryle d'inhibition de la kinase | |
| MX392098B (es) | Anticuerpos neutralizantes de poliomavirus. | |
| EP3423100A4 (en) | COMPOSITIONS FOR THE TREATMENT OF INFLAMMATION AND METHOD FOR THE TREATMENT THEREOF | |
| MX376201B (es) | Compuestos inhibidores de metaloenzima. | |
| BR112017003571A2 (pt) | terapia combinada | |
| MX2018012493A (es) | Métodos para controlar y tratar el cáncer. | |
| EP3603636A4 (en) | COMPOSITION TARGETING S1PR4 TO PREVENT OR TREAT NON-ALCOHOLIC STEATOHEPATITIS | |
| BR112018071467A2 (pt) | método de tratamento ou prevenção de patologias hepáticas | |
| EP3644983A4 (en) | COMPOSITIONS AND METHODS OF TREATMENT OR PREVENTION OF FIBROTIC LUNG DISEASES | |
| EP3313186A4 (en) | LPT-723 AND IMMUNE CONTROL POINT COMBINATIONS AND TREATMENT PROCEDURES | |
| IL269363A (en) | Methods for measuring therapeutic effects of retinal disease therapies | |
| MA45226A (fr) | Compositions et méthodes de traitement ou de prévention d'affections liées à l'oxalate | |
| EP3592355A4 (en) | METHODS FOR TREATMENT AND / OR PREVENTION OF ACTINIC KERATOSIS | |
| BR112019005539A2 (pt) | métodos de tratamento de lesão renal aguda | |
| BR112015019564A2 (pt) | tratamento de esclerose múltipla com laquinimod |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI N? 10196/2001, QUE MODIFICOU A LEI N? 9279/96, A CONCESS?O DA PATENTE EST? CONDICIONADA ? ANU?NCIA PR?VIA DA ANVISA. CONSIDERANDO A APROVA??O DOS TERMOS DO PARECER N? 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL N? 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVID?NCIAS CAB?VEIS. |
|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B06I | Publication of requirement cancelled [chapter 6.9 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2631 DE 08/06/2021 POR TER SIDO INDEVIDA. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B154 | Notification of filing of divisional application [chapter 15.50 patent gazette] |
Free format text: O PEDIDO FOI DIVIDIDO NO BR122024002810-7 PROTOCOLO 870240011932 EM 09/02/2024 17:43. |
|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B12B | Appeal against refusal [chapter 12.2 patent gazette] |